Objective
Crimean-Congo haemorrhagic fever (CCHF) is febrile dengue-like disease of man caused by strains of a nairovirus (Bunyaviridae family) of the CCHF serogroup. This tick-borne zoonosis is an important human disease in Eastern Europe, the Middle East, Asia, and most of Africa. The health impact of CCHF in Africa is unknown; the disease is probably underdiagnosed This is partly because of the lack of commercially available diagnostic: kits. Serological tests can be carried out by a few laboratories but are hazardous because live virus is used, and are frequently unreliable in terms of sensitivity and specificity. Rapid tests for directly detecting the virus are not available. The project aims to establish rapid diag- . nostic methods for the detection of CCHF virus infections, and to develop a vaccine. Diagnost coprobes and reagents will be produced using recombinant DNA technology based on the cloning and sequencing of the small- (S) and medium- (M) sized RNA segments of the tripartite nairovirus genome. Primers and probes will be designed that can rapidly and specifically detect CEHF viral RNA in blood and tissue samples, and in vector ticks. Early diagnosis of disease in humans is essential for the prognosis of the patient and for hospital staff who need to protect against nosocomial infections. Recombinant proteins derived from the viral nucleoprotein and glycoprotein will be used in immunoassays for detection of antibodies in human and non-human sera. Diagnostic tests will be performed in the collaborating African laboratories and established as routine procedures for screening human populations, and identifying and monitoring enzootic foci. Training in reagent preparation and diagnostic techniques will be provided by the proposers. The reagents and techniques employed will reduce the health risk of exposure to CCHF virus during diagnostic cedures. Experimental protection studies undertaken with the collaborating African laboratories will employ recombinant proteins and non-pathoaenic nairoviruses to assess their potential as vaccines. This work will assess
the feasibility of targeted immunisation of high risk group in both human and livestock podulations, and the control of human exposure to virus infected ticks.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology immunisation
- natural sciences biological sciences microbiology virology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- natural sciences biological sciences genetics RNA
- medical and health sciences health sciences public health epidemiology zoonosis
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
54006 Thessaloniki
Greece
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.